Overcoming Chronic Myeloid Leukemia Stem Cell Resistance to Imatinib by Also Targeting JAK2

被引：5
作者：
Cogle, Christopher R. [1 ]
机构：
[1] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL 32610 USA
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2013年 / 105卷 / 06期
关键词：
BCR-ABL; INHIBITOR; AHI-1;
D O I：
10.1093/jnci/djt029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：378 / 379
页数：2
相关论文
共 9 条
  • [1] Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
    Bhatia, R
    Holtz, M
    Niu, N
    Gray, R
    Snyder, DS
    Sawyers, CL
    Arber, DA
    Slovak, ML
    Forman, SJ
    [J]. BLOOD, 2003, 101 (12) : 4701 - 4707
  • [2] Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1BCR-ABL-JAK2 Complex
    Chen, Min
    Gallipoli, Paolo
    DeGeer, Donna
    Sloma, Ivan
    Forrest, Donna L.
    Chan, Matthew
    Lai, Damian
    Jorgensen, Heather
    Ringrose, Ashley
    Wang, Hui Mi
    Lambie, Karen
    Nakamoto, Helen
    Saw, Kyi Min
    Turhan, Ali
    Arlinghaus, Ralph
    Paul, James
    Stobo, Jon
    Barnett, Michael J.
    Eaves, Allen
    Eaves, Connie J.
    Holyoake, Tessa L.
    Jiang, Xiaoyan
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (06): : 405 - 423
  • [3] Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
    Corbin, Amie S.
    Agarwal, Anupriya
    Loriaux, Marc
    Cortes, Jorge
    Deininger, Michael W.
    Druker, Brian J.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (01) : 396 - 409
  • [4] Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia
    Jiang, XY
    Zhao, Y
    Chan, WY
    Vercauteren, S
    Pang, E
    Kennedy, S
    Nicolini, F
    Eaves, A
    Eaves, C
    [J]. BLOOD, 2004, 103 (10) : 3897 - 3904
  • [5] TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
    Pardanani, A.
    Hood, J.
    Lasho, T.
    Levine, R. L.
    Martin, M. B.
    Noronha, G.
    Finke, C.
    Mak, C. C.
    Mesa, R.
    Zhu, H.
    Soll, R.
    Gilliland, D. G.
    Tefferi, A.
    [J]. LEUKEMIA, 2007, 21 (08) : 1658 - 1668
  • [6] Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia
    Samanta, A.
    Perazzona, B.
    Chakraborty, S.
    Sun, X.
    Modi, H.
    Bhatia, R.
    Priebe, W.
    Arlinghaus, R.
    [J]. LEUKEMIA, 2011, 25 (03) : 463 - 472
  • [7] Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
    Traer, E.
    MacKenzie, R.
    Snead, J.
    Agarwal, A.
    Eiring, A. M.
    O'Hare, T.
    Druker, B. J.
    Deininger, M. W.
    [J]. LEUKEMIA, 2012, 26 (05) : 1140 - 1143
  • [8] Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
    Verstovsek, Srdan
    Kantarjian, Hagop
    Mesa, Ruben A.
    Pardanani, Animesh D.
    Cortes-Franco, Jorge
    Thomas, Deborah A.
    Estrov, Zeev
    Fridman, Jordan S.
    Bradley, Edward C.
    Erickson-Viitanen, Susan
    Vaddi, Kris
    Levy, Richard
    Tefferi, Ayalew
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12) : 1117 - 1127
  • [9] AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
    Zhou, Liang L.
    Zhao, Yun
    Ringrose, Ashley
    DeGeer, Donna
    Kennah, Erin
    Lin, Ann E. -J.
    Sheng, Guoqing
    Li, Xiao-Jiang
    Turhan, Ali
    Jiang, Xiaoyan
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (11) : 2657 - 2671
1